



LKT Laboratories, Inc.

AZD-8186

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A985132

CAS No. 1627494-13-6

Chemical Name

Synonym AZD 8186, AZD8186

Formula $C_{24}H_{25}F_2N_3O_4$

Formula Wt. 457.48

Melting Point


Purity $\geq 99\%$

Solubility

Store Temp -20°C

Ship Temp Ambient

Description AZD-8186 is a potent and selective inhibitor of PI3KB and PI3K δ . It shows efficacy against PTEN-null tumors, which become dependent on the PI3KB isoform. The loss of the PTEN protein results in upregulation of the PI3K/AKT pathway, making small molecules that target PI3KB viable in cancers like PTEN-deficient breast and prostate tumors.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
A985132	5 mg	\$71.40
A985132	25 mg	\$227.20
A985132	100 mg	\$713.80

References Barlaam B., Cosulich S., et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3KB and PI3K δ for the treatment of PTEN-deficient cancers. *J Med Chem.* 58(2):943-62 (2015). PMID: 25514658.

Lynch J., Planska U., et al. Inhibiting PI3KB with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. *Clin Cancer Res.* 23(24):7584-95 (2017). PMID: 28972046.

Hancox U., Cosulich S., et al. Inhibition of PI3KB signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. *Mol Cancer Ther.* 14(1):48-58 (2015). PMID: 25398829.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.